Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Sitravatinib”

33 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 33 results

Early research (Phase 1)Study completedNCT04518046
What this trial is testing

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Who this might be right for
Clear-Cell Renal Cell Carcinoma
Mirati Therapeutics Inc. 22
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Early research (Phase 1)Study completedNCT04887194
What this trial is testing

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Who this might be right for
Advanced Solid Tumor
Mirati Therapeutics Inc. 40
Testing effectiveness (Phase 2)Looking for participantsNCT05407519
What this trial is testing

Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Who this might be right for
Hepatocellular Carcinoma
Anhui Provincial Hospital 40
Testing effectiveness (Phase 2)WithdrawnNCT05419817
What this trial is testing

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System

Who this might be right for
Recurrent Endometrial CancerSolid Tumors
Haider Mahdi
Early research (Phase 1)Study completedNCT04772612
What this trial is testing

Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Who this might be right for
Hepatic Impairment
Mirati Therapeutics Inc. 30
Testing effectiveness (Phase 2)Ended earlyNCT04925986
What this trial is testing

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung DiseasesLung Neoplasms+6 more
Sarah Goldberg 9
Testing effectiveness (Phase 2)Study completedNCT02978859
What this trial is testing

Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Who this might be right for
LiposarcomaMetastatic Liposarcoma
Columbia University 29
Large-scale testing (Phase 3)Study completedNCT03906071
What this trial is testing

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics Inc. 577
Large-scale testing (Phase 3)Ended earlyNCT04921358
What this trial is testing

Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
BeiGene 377
Large-scale testing (Phase 3)WithdrawnNCT05564338
What this trial is testing

Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
BeiGene
Early research (Phase 1)Study completedNCT04935112
What this trial is testing

Explore the Effect of Acid-reducing Agents

Who this might be right for
Healthy Adults
Mirati Therapeutics Inc. 15
Testing effectiveness (Phase 2)Study completedNCT03941873
What this trial is testing

Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Carcinoma, HepatocellularGastric/Gastroesophageal Junction Cancer
BeiGene 111
Testing effectiveness (Phase 2)UnknownNCT04734262
What this trial is testing

A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Who this might be right for
Metastatic Breast Cancer
Fudan University 98
Early research (Phase 1)Study completedNCT02219711
What this trial is testing

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Mirati Therapeutics Inc. 193
Testing effectiveness (Phase 2)Ended earlyNCT05176925
What this trial is testing

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Fudan University 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT04727996
What this trial is testing

Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer

Who this might be right for
Advanced Biliary Tract Cancer
Seoul National University Hospital 43
Testing effectiveness (Phase 2)Ended earlyNCT04123704
What this trial is testing

Sitravatinib in Metastatic Breast Cancer

Who this might be right for
Breast Cancer Stage IVTriple Negative Breast CancerBreast Neoplasms+1 more
Xiang Zhang 3
Testing effectiveness (Phase 2)Ended earlyNCT02954991
What this trial is testing

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Mirati Therapeutics Inc. 161
Testing effectiveness (Phase 2)Study completedNCT03015740
What this trial is testing

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Who this might be right for
Clear Cell Renal Cell CarcinomaMetastatic Kidney CarcinomaStage III Renal Cell Cancer AJCC v7+1 more
M.D. Anderson Cancer Center 42
Load More Results